Continued Investigations are Pertinent for FDA Approvals in the Treatment of Patients With EGFR-mutated NSCLC
Jason Porter, MD, highlights the implications of recent data to emerge following the use of EGFR TKIs in the adjuvant setting, the importance of the potential upcoming FDA approval of osimertinib with chemotherapy in EGFR-positive non–small cell lung cancer, and more.
Source: onclive.com